Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed <i>FLT3</i> Mutated AML
Selina M. Luger(University of Pennsylvania), Mark R. Litzow(Dana-Farber Cancer Institute), Mithun Vinod Shah(Mayo Clinic in Arizona), Sameem Abedin(Medical College of Wisconsin), Jessica K. Altman(Northwestern University), Deepa Jeyakumar(Dana-Farber Cancer Institute), James M. Foran(Memorial Sloan Kettering Cancer Center), Alexander E. Perl(University of Pennsylvania), Robert L. Redner(UPMC Hillman Cancer Center), Ayman Qasrawi(University of Kentucky), Keith W. Pratz(University of Pennsylvania), Sanam Loghavi(The University of Texas MD Anderson Cancer Center), Ashwin Kishtagari(Memorial Sloan Kettering Cancer Center), Vamsi Kota(Augusta University), Jonathan E. Kolitz(Memorial Sloan Kettering Cancer Center), Lindsay Wilde(Thomas Jefferson University), Amir T. Fathi(Harvard University), Krishna Gundabolu(University of Nebraska Medical Center), Emily Curran(University of Cincinnati), Li Chen(Qingdao University), Zhuoxin Sun(Dana-Farber Cancer Institute), Adam S. Asch(Cornell University), Ellin Berman(Memorial Sloan Kettering Cancer Center), Kelly Ross(West Virginia University), Kristen M. O’Dwyer(University of Rochester Medical Center)
Cited by 7
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
|Nature Genetics|2011|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k